Zhongkai Shi

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans

Kent R. Van Kampen, Zhongkai Shi, Peng Gao et al. · Vaccine · 2004 · 224 citations

Veterinary Medicine, Immunology, Infectious Diseases +14

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Angelique Kany Kany Luabeya, Benjamin M. Kagina, Michèle Tameris et al. · Vaccine · 2015 · 194 citations

Veterinary Medicine, Immunology, Infectious Diseases +15

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial

Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 117 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

DNA-based non-invasive vaccination onto the skin

Zhongkai Shi, David T Curiel, De‐chu C. Tang · Vaccine · 1999 · 87 citations

Pharmacy, Biotechnology, Molecular Biology +12

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

Hennie Geldenhuys, Helen Mearns, David J. C. Miles et al. · Vaccine · 2015 · 79 citations

Life Sciences, Immunology, Infectious Diseases +14